Background {#Sec1}
==========

Urinary tract stones' localization is usually on the kidney, while ureteral stones make up 20% of all urinary system stones \[[@CR1]\]. Patients with a ureteral stone usually present with complaints such as flank pain, nausea-vomiting, and lower urinary tract symptoms \[[@CR1], [@CR2]\]. The most important parameter in determining the treatment to be applied is the size of the ureteral stones. Ureteral stones classified as non-complicated and smaller than 10 mm in diameter may be followed up for a month due to the possibility of spontaneous passage (SP).

Medical expulsive therapy (MET) is a non-invasive treatment modality that is especially recommended for ureteral stones \> 5 mm. MET consists of high fluid intake and medical agents such as anti-inflammatory drugs, alpha-blockers, calcium channel blockers, corticosteroids or phosphodiesterase inhibitors. It has been proven elsewhere that the likelihood and speed of spontaneous passage are increased with MET \[[@CR1], [@CR3]\]. Furthermore, MET decreases hospital visits, costs, and the requirement of interventional treatment \[[@CR4]--[@CR7]\].

Ureteral stones can cause inflammation in the ureteral wall, and this mucosal inflammation was found to be related to the impaction of the stone. In studies using serum inflammation markers to predict the impaction of ureteral stones, serum white blood cell (WBC), neutrophil count, c-reactive protein (CRP), and neutrophil-lymphocyte ratio (NLR) values were found to be related to the spontaneous passage of ureteral stones \[[@CR8]--[@CR11]\].

Procalcitonin is a polypeptide consisting of 116 amino acids, with a molecular weight of approximately 13 kilodaltons. Ghillani et al., 1989, first described this hormone as the precursor of calcitonin, which is made up of 32 amino acids \[[@CR12]\]. In sepsis and inflammation, serum procalcitonin levels have been shown to increase following release of endotoxins and immunomodulators \[[@CR13]\]. Furthermore, it has been reported that the elevation of procalcitonin may be used to indicate a relapse of chronic prostatitis, the rate of infection in obstructed ureteral stones, and the severity of inflammation in cholecystitis \[[@CR14]--[@CR16]\].

Despite MET, the spontaneous passage of ureteral stones smaller than 10 mm may not be observed in clinical practice. In recent years, many studies have investigated the reasons behind this circumstance \[[@CR10], [@CR11]\]. In light of these studies, we aimed to investigate the effect of serum procalcitonin and other inflammation markers at the time of diagnosis, for patients with ureteral stones sized 5-10 mm.

Methods {#Sec2}
=======

This prospective observational study was conducted between August and November of 2016, after receiving institutional review board approval. The patients gave informed consent for participation at the beginning of the study.

Patients aged 20 to 60 years with renal colic and having a single distal ureteral stone 5-10 mm in diameter, detected by an unenhanced CT scan, were included in this study. Exclusion criteria from the study were the patients with severe hydronephrosis, symptomatic urinary system infection, findings of acute renal failure, congenital ureteral anomaly, a history of ureteral stenosis or reconstructive ureteral surgery, and those who had received anti-inflammatory or anti-microbial drugs for the ureteral stone. Patients with active infective disease, chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis), active neoplasia, thyroid disease with or without thyroid surgery, immunosuppression or immunosuppressive treatment were also excluded from the study. The control group included 33 healthy volunteers of the same age range and socio-demographic characteristics, no history of stone disease and no active or chronic disease.

The patients' characteristics including age, gender, BMI (body mass index), smoking history, chronic illnesses, drug allergies, previous stone interventions (nephropyelolithotomy, percutaneous surgery, URS-L or ESWL) were all recorded. Unenhanced abdominal CT scans were used to determine the stone size (dimension at its greatest diameter), area (width x length × 0.8), laterality (left/right), and the degree of hydronephrosis.

Complete blood cell count, C-reactive protein (CRP), sedimentation, serum procalcitonin, urinalysis and urine culture were performed for both groups. In the complete blood cell count, values for white blood cells (WBC), neutrophil/lymphocyte ratio (NLR), mean platelet volume (MPV), and red cell distribution width (RDW) were noted. In the urinalysis, the presence or absence of leucocyturia and bacteriuria were noted. The BioVendor® (Czechia) Human Procalcitonin ELISA (RD191006200R) kit was used to measure the procalcitonin level. Serums were analyzed using the Biotek Elx-800 microplate reader and Biotek Gen5 software.

All patients received diclofenac sodium 75 mg/day, tamsulosin 0.4 mg/day and at least 3 l/day fluid intake. The patients were followed up with kidney, ureter, bladder (KUB) plain films, ultrasonography (USG) and unenhanced abdominal CT scan every 2 weeks for 1 month unless emergency situations appeared. Patients with stone-free status at follow-up were concluded to have achieved complete stone passage \[SP(+)\], and failure \[SP(−)\] was concluded if the patient had not passed the stone by the end of the study.

Statistical analyses {#Sec3}
--------------------

Mean, standard deviation, median, lowest and highest scores, frequency and ratio values were used for the descriptive statistics of the data. Distribution of variables was obtained using the Kolmogorov Smirnov test. The Mann-Whitney U test was utilized for analyses of the independent quantitative data. For the analyses of independent categorical data, the chi square test was preferred, and when it was not applicable, Fischer's exact test was substituted. Impact level and cut-off values were determined using the ROC curve. The effect level was investigated by univariate and multivariate logistic regression. All analyses were conducted with SPSS 22.0; the accepted level of statistical significance was *p* \< 0.05.

Results {#Sec4}
=======

According to the exclusion criteria, 11 patients were excluded from the study, and the data of the case (*n* = 54) and control (*n* = 33) groups were analyzed. None of the patients showed symptoms requiring intervention treatment, such as high fever, renal colic attacks that cannot be controlled with analgesics, progressive hydronephrosis or renal failure, during the follow-up period.

There were no significant differences between the case and the control groups in terms of bacteriuria ratio, WBC or CRP values. However, the leucocyturia ratio, RDW, NLR, sedimentation and procalcitonin values were significantly higher in the case group (*p* \< 0.05) (Table [1](#Tab1){ref-type="table"}). Table 1Comparison of case and control groups's sosyodemographic characteristics and biochemichal inflammation markersCase GroupControl GroupP**Age (years)**37,1 ± 10,233,9 ± 8,30,159**Gender**Male 38 (70,4%)Male 27 (81,8%)0,233**BMI (kg/m**^**2**^**)**26,5 ± 4,124,8 ± 5,10,245**WBC (10**^**3**^**/**μL**)**8,8 ± 2,38,0 ± 1,90,553**RDW (%)**15,5 ± 1,912,8 ± 0,9**0,000NLR (%)**2,8 ± 1,72,0 ± 0,3**0,009MPV (fL)**8,6 ± 1,08,5 ± 0,70,451**CRP (mg/L)**10,4 ± 12,64,0 ± 1,10,088**Sedimentation (mm/h)**13,4 ± 9,94,2 ± 1,3**0,000Procalcitonin (pg/ml)**165,7 ± 104,7128,2 ± 36,6**0,004Bacteriuria (+)**3,7%0%0,524**Leucocyturia (+)**37%0%**0,000***BMI* Body mass index; *WBC* White blood cell; *NLR* Neutrophil-lymphocite ratio; *MPV* Mean platelet volume; *CRP* C-reactive protein

Based on the follow-up controls, 30 patients (55.5%) passed the stone \[SP(+)\], whereas passage did not occur in 24 patients (44.5%) \[SP(−)\]. Age, gender, BMI, smoking history, and previous stone-related intervention rates were similar in both groups except stone distributions (*p* \< 0.05) (Table [2](#Tab2){ref-type="table"}). Table 2Sosyodemographic characteristics and stone history of SP(−) and SP(+) groupsSP(−)SP(+)p**Age (years)**35,8 ± 9,338,0 ± 10,90,381**Gender (F/M) %**41,7/58,320/800,083**BMI (kg/m**^**2**^**)**26,4 ± 4,726,5 ± 3,60,781**Smoking history**%50%53,30,808**Previous ESWL**%12,5%16,70,668**Previous Stone surgery**%8,3%6,70,816**Stone burden (mm**^**2**^**)**30 ± 8.229.1 ± 10.30,310**Stone distrubition (R/L)**16/1413/110,745*BMI* Body mass index; *ESWL* Extracorporeal shock wave lithotripsy

Between the SP(−) and SP(+) groups, bacteriuria ratios, WBC, RDW, NLR, MPV, CRP, and sedimentation values were not significantly different (*p* \> 0.05).

Compared to the SP (+) group, mean serum procalcitonin levels (207 ± 145.1 vs 132.7 ± 28.1 pg/ml, *p* = 0.000) and the leucocyturia ratio (58.3 vs. 20%, *p* = 0.004) were significantly higher in the SP (−) group (Table [3](#Tab3){ref-type="table"}). Based on the ROC curve analysis, 160 pg/ml (86.7% sensitivity, 70.8% specificity, *p* \< 0.001; AUC: 0.788 95% CI (0.658--0.917) was identified as the optimal cut-off value for procalcitonin (Fig. [1](#Fig1){ref-type="fig"}). In logistic regression analysis, a significant efficacy of procalcitonin and leucocyturia was observed in the univariate analysis of spontaneous passage. In the multivariate analysis, significant independent activity was observed with procalcitonin. (Table [4](#Tab4){ref-type="table"}) (*p* \< 0.05). Table 3Effect of biochemichal inflammation markers for spontaneous ureteral stone passageSP(−)SP(+)p**WBC (10**^**3**^**/μL)**8,4 + 2,39,1 + 2,40,261**RDW (%)**15,5 + 2,415,4 + 1,50,657**NLR (%)**2,8 + 1,72,9 + 1,70,821**MPV (fL)**8,7 + 0,68,5 + 1,30,721**CRP (mg/L)**9,0 + 8,211,5 + 15,40,875**Sedimentation (mm/h)**11,8 + 714,7 + 11,70,558**Procalcitonin (pg/ml)**207 + 145,1132,7 + 28,1**0,000Leucocyturia (+)(%)**58,3%20%**0,004***WBC* White blood cell; *NLR* Neutrophil-lymphocite ratio; *MPV* Mean platelet volume; *CRP* C-reactive proteinFig. 1ROC curve for cutoff value of 160 pg/ml of procalcitonin on prediction of spontaneous ureteral stone passageTable 4Logistic regression analysis for spontaneous passage in 5-10 mm distal ureteral stonesUnivariate analysisMultivariate analysisOR95% Confidence IntervalpOR95% Confidence Intervalp**Age (years)**1,020,97-1,080,447**Gender**2,860,85-9,560,088**BMI**1,000,88--1,150,962**Primary/secondary**1,270,43-3,820,665**History of SWL**0,960,32-2,930,950**History of stone passage**1,400,30-6,560,669**History of stone surgery**0,790,10-6,030,817**Smoking history**1,140,39-3,350,808**Hydronephrosis**0,580,19-1,720,326**Stone burden**0,990,95-1,040,732**WBC**1,140,89-1,460,287**RDW**0,970,73-1,280,807**NLR**1,030,74-1,430,855**MPV**0,840,47-1,480,547**CRP**1,020,97-1,070,470**Sedimentation**1,030,97-1,100,307**Procalcitonin**0,960,94-0,99***0,002***0,940,89- 0,98***0,005*Leucocyturia**0,180,05-0,60***0,005****BMI* Body mass index; *ESWL* Extracorporeal shock wave lithotripsy; *WBC* White blood cell; *NLR* Neutrophil-lymphocite ratio; *MPV* Mean platelet volume; *CRP* C-reactive protein

Discussion {#Sec5}
==========

Observation with MET protocol, ESWL and URS-L are the treatment options for the ureteral stones and could be preferred based on the patient's clinical condition and size of the stone. Treatment success for ESWL and URS-L depends on localization and size of the stone and is reported to be 68--90% and 80--97% respectively \[[@CR1]\]. Even though high success rates occur from these treatment modalities, high costs and complication risks must be weighed as to their primary disadvantages \[[@CR17], [@CR18]\]. Moreover, the financial burden of having additional laboratory tests is another controversy about whether a ureteral stone can be spontaneously evacuated or not \[[@CR18]\]. Similarly, complications such as recurrent renal colic attacks, urosepsis, and urinary tract infections may occur; observation or MET is therefore to be preferred for those patients. During the observation, ureteral stone impaction may also be observed due to ureteral mucosal inflammation, resulting in a more difficult and complicated treatment process of the ureteral stone \[[@CR11]\]. For these reasons, accurate prediction of spontaneous passage has taken on greater importance in recent years, and several studies have been conducted in this area.

Recent studies have determined the likelihood of spontaneous passage in ureteral stones \< 5 mm to be 71--100%, and 25--46% in stones measuring 5-10 mm. Also, for ureteral stones \< 4 mm, the possibility of spontaneous passage within 40 days was reported to be 95% \[[@CR1], [@CR19]\]. One study classified stones into three groups based on size and reported spontaneous passage rates of 89.9, 63.4 and 9.1% for \< 5 mm, 5-10 mm and \> 10 mm ureteral stones, respectively \[[@CR20]\]. In another study, which compared observation and MET for 5-10 mm ureteral stones, SP ratios were reported to be 50 and 81.8% respectively \[[@CR21]\]. In our study, when medical expulsive therapy was conducted for the 5-10 mm ureteral stones, the SP rate was calculated to be 55.5%.

Another important factor affecting the possibility of SP in ureteral stones is localization. Studies indicate that as the stone approaches to distal, both the SP ratio and the greatest benefit from MET increase \[[@CR22]--[@CR24]\]. Although MET was employed in our study, the SP rate was lower than in other studies. AUA panels showed superior SFR for patients treated with MET (77.3%) compared with placebo (54.4%) on distal ureteral stones \< 10 mm \[[@CR22]\]. We believe that the lower rate of SFR (55.5%) in our study was due to the 5-10 mm stone size in the patients in our research.

Lifestyle factors, such as smoking habits and sexual intercourse, have also been investigated in recent years as potential factors of spontaneous passage. Fazlıoğlu et al. reported similar SP ratios in \< 4 mm distal ureter stones for smokers and non-smokers, but for ≥ 4 mm distal ureter stones, the SP ratio was reported to be lower in smokers \[[@CR25]\]. In another study, Bayraktar et al. investigated three groups of patients with 5-10 mm distal ureteral stones receiving different treatments. Group 1 received tamsulosin 0.4 mg/day, Group 2 was asked to have intercourse three times per week, and Group 3 received medical treatment. The authors reported that, based on their results, having sexual intercourse three times a week could be as beneficial as tamsulosin treatment \[[@CR26]\]. We also compared SP levels in terms of BMI and smoking habits, but the differences were not significant (*p* \> 0.05).

In recent years, the effect of some biochemical factors on the SP ratio has been reported. Ahmed et al. reported that patients with small stones, distal localization, high serum WBC level, low perinephric fat thickness, and lack of tissue-rim sign had increased SP ratios \[[@CR27]\]. Similarly, another study reported significant correlations between the increase of WBC and neutrophil levels and the SP ratio, in \< 10 mm ureteral stones (*p* \< 0.001) \[[@CR11]\]. According to the authors, this correlation was associated with increased ureteral peristalsis, caused by inflammation in the ureteral wall. By contrast, Aldaqodossi et al. reported that an increase in ureteral inflammation could decrease the SP ratio \[[@CR8]\]. In this study, the authors reported that the SP(−) group was significantly higher than the SP(+) group for initial CRP values (*p* = 0.001). Furthermore, based on ROC curve analysis, it was found that sensitivity and specificity of the 21.9 mg/dl cut-off value for CRP, were 78.6 and 89.3% respectively \[[@CR8]\]. In our study, the mean serum WBC value was higher in the SP(+) group, when compared to the SP(−) group (9.1 ± 2.4 vs. 8.4 ± 2.3), although this difference is not statistically significant. Similarly, mean CRP values were higher in the SP(+) group (11.5 ± 15.4) than in the SP(−) group (9.0 ± 8.2), and again, there is no statistically significant difference.

To our knowledge, the available literature does not include a study investigating the effect of serum procalcitonin on SP. However, procalcitonin has been reported to be valuable in showing a correlation between urinary tract infection and impacted ureteral stones. Papagiannopoulos et al. reported that procalcitonin \> 100 pg/ml was detected in 18% of patients treated with MET, 45% of whom had undergone URS-L or ureteral stenting \[[@CR16]\]. In our study, the mean serum procalcitonin level of the SP(−) group (207.0 ± 145.1 pg/ml) was significantly higher than in the SP(+) group (132.7 ± 28.1 pg/ml) (*p* = 0.000). Furthermore, leucocyturia rates of the SP(−) group were significantly higher than in the SP(+) group (58.3% vs. 20%) (*p* = 0.004). This finding could better explain the relationship between high serum procalcitonin and mucosal inflammation. It has been reported in previous studies that leucocyturia did not effect on spontaneous passage; this finding should be re-evaluated through studies with larger sample sizes \[[@CR9], [@CR27]\].

The fact that procalcitonin is significant even in multivariant analysis increases the possibility of using this marker in daily practice in the future. Of course, the accuracy of this information should be supported by a larger series.

Based on these results, it could be argued that procalcitonin plays a role in predicting SP, but this hypothesis needs to be supported with studies having higher sample sizes. Also, measuring the procalcitonin level again at the end of the study could increase the strength of the study. Our sample size was not large enough for subgroup analysis, a limitation of our study. Particularly, evaluating the serum procalcitonin and leucocyturia through subgroup analysis may provide a more objective argument for our hypothesis.

Conclusion {#Sec6}
==========

This study reports that distal ureteral stones sized 5-10 mm presenting with high procalcitonin levels and leucocyturia may have a negative effect on spontaneous passage. This relationship can be explained by stone impaction, possibly caused by increased mucosal inflammation.
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